Meeting
2014 ASCO Annual Meeting
Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal women with early breast cancer.
Authors
Katherine Elizabeth Reeder-Hayes
Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Katherine Elizabeth Reeder-Hayes , Shellie D. Ellis , Stacie Dusetzina , Stephanie B. Wheeler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Cost
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6565)
DOI
10.1200/jco.2014.32.15_suppl.6565
Abstract #
6565
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis.
First Author: Walter Gregory
Poster
2021 ASCO Annual Meeting
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
First Author: Vladislav Berdunov
Poster
2019 ASCO Annual Meeting
Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.
First Author: Darya Kizub
Poster
2018 ASCO Annual Meeting
Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab.
First Author: Raul A Herrera Pena